In Q1 FY2026 (ended March 31, 2026), DaVita reported revenue of $3.416 billion, up 6.0% year-over-year. Net income rose 21.2% to $197.5 million, and diluted EPS increased 43.5% to $2.87. Operating income grew 9.8% to $481.9 million. The company held $644.2 million in cash and had negative equity of $755.5 million.
•Revenue increased 6.0% YoY to $3.416 billion.
•Net income rose 21.2% to $197.5 million.
•Diluted EPS grew 43.5% to $2.87.
•Cash balance was $644.2 million; equity was negative $755.5 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
DaVita provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers Outpatient, hospital inpatient, and home-based hemodialysis dialysis services.
Its portfolio also includes operates clinical laboratories that provide routine laboratory tests for dialysis and physician-prescribed laboratory tests for ESRD patients, and management and administrative services to outpatient dialysis centers.
Additionally, it offers integrated care and disease management services to patients in risk-based and integrated care arrangements. Its portfolio also includes clinical research programs, physician services, and comprehensive kidney care services, as well as the transplant software business. Incorporated in 1994 and headquartered in Denver, Colorado, DaVita was formerly known as DaVita HealthCare Partners Inc. before rebranding in September 2016.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and offers related lab services in outpatient dialysis centers, as well as outpatient, hospital inpatient, and home-based hemodialysis services. Its portfolio also includes clinical laboratories that perform routine tests for dialysis and physician-prescribed tests for end-stage renal disease (ESRD) patients. Additionally, DaVita provides management and administrative services to outpatient dialysis centers, integrated care and disease management services under risk-based arrangements, clinical research programs, physician services, comprehensive kidney care services, and a transplant software business.
Where is DaVita (DVA) listed and what currency does it trade in?
DaVita Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol DVA. The company trades in United States dollars (USD), as it is headquartered in the United States and its primary listing is on a U.S. exchange.
What sector and industry does DaVita (DVA) operate in?
DaVita Inc. operates in the Healthcare sector, specifically within the Medical Care Facilities industry. This means the company is involved in providing medical care services in facility-based settings, primarily focusing on kidney dialysis treatment for patients with chronic kidney failure.
Where is DaVita (DVA) headquartered and what markets does it serve?
DaVita Inc. is headquartered in Denver, Colorado, United States. The company primarily serves the U.S. market, operating kidney dialysis centers and providing related services across the country. Its services include outpatient dialysis, hospital inpatient dialysis, home-based hemodialysis, and clinical laboratory services for ESRD patients.
How does DaVita (DVA) make money?
DaVita generates revenue primarily by providing kidney dialysis services to patients with chronic kidney failure. The company operates outpatient dialysis centers where patients receive regular treatments, and it also offers home-based hemodialysis services. Additionally, DaVita earns income from its clinical laboratories that perform routine and physician-prescribed tests for dialysis patients. The company provides management and administrative services to other outpatient dialysis centers, as well as integrated care and disease management services under risk-based arrangements. Other revenue streams include clinical research programs, physician services, comprehensive kidney care services, and a transplant software business.